Sugi Predict

Sugi Predict / Compounds / SCHEMBL16759178

SCHEMBL16759178

SCHEMBL16759178

Clc1cc(Cl)cc(C[C@@H]2CNCCO2)c1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ EPHA2 P29317 1/20 0.39
▸ SLC6A4 P31645 11/20 0.38
▸ SLC6A2 P23975 9/20 0.38
▸ SLC6A3 Q01959 5/20 0.38
▸ HTR2A P28223 3/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ HTR1A P08908 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ KCNH2 Q12809 1/20 0.36
▸ USP7 Q93009 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17061727 1.00 EPHA2 (0.39) EPHA2SLC6A4SLC6A2SLC6A3HTR2A
SCHEMBL1552432 0.84 HTR2B (0.41) EPHA2SLC6A4SLC6A2SLC6A3HTR2A
SCHEMBL1552434 0.84 HTR2B (0.41) EPHA2SLC6A4SLC6A2SLC6A3HTR2A
SCHEMBL2380011 0.84 SLC6A3 (0.41) SLC6A4SLC6A2SLC6A3HTR2AADRB2
SCHEMBL1552398 0.81 SLC6A2 (0.50) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL1552397 0.81 SLC6A2 (0.50) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL16759290 0.81 SLC6A2 (0.50) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL1552774 0.80 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3HTR2AKCNH2
SCHEMBL1551924 0.78 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3HTR2AADRB2
SCHEMBL1551928 0.78 SLC6A2 (0.46) SLC6A4SLC6A2SLC6A3HTR2AADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 — — US disclosed
US-11149002-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-10-19 — — US disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 — — US disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 — — US disclosed
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-03-18 — — US disclosed
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-03-18 — — US disclosed
US-20200108054-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2020-04-09 — — US disclosed
CN-105793238-B Substituted benzamides and methods of use thereof 基因泰克公司 2019-12-24 — — CN disclosed
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 — — EP disclosed
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 — — EP disclosed
US-9546164-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-01-17 — — US disclosed
US-9546164-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-01-17 — — US disclosed
EP-3074377-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2016-10-05 — — EP disclosed
CN-105793238-A Substituted benzamides and methods of use thereof 基因泰克公司 2016-07-20 — — CN disclosed
WO-2016007534-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-01-14 — — WO disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed
WO-2015078374-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-06-04 — — WO disclosed
WO-2015078374-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149002-B2 Therapeutic compounds and methods of use thereof RDX, C1R, MTX1 EPHA2 719/4885SLC6A4 1914/4885SLC6A2 1205/4885
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 EPHA2 4209/4885SLC6A4 1222/4885SLC6A2 1283/4885
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, RRM1 EPHA2 4525/4885SLC6A4 1432/4885SLC6A2 1679/4885
US-20210078947-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 EPHA2 719/4885SLC6A4 1914/4885SLC6A2 1205/4885
US-20200108054-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 EPHA2 4209/4885SLC6A4 1222/4885SLC6A2 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.